Latest News-CliniExpert

FDA Approves Zegalogue (dasiglucagon) Injection for the Treatment of Severe Hypoglycemia in People with Diabetes

Copenhagen, DK and Boston, MA, U.S. March 22, 2021 -- Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078,) a biotechnology company aspiring to deliver innovation with novel peptide therapeutics, anno

HERTHENA-Lung01 Phase 2 Study of Daiichi Sankyo’s Patritumab Deruxtecan Initiated in Patients with EGFR-Mutated NSCL

Tokyo, Basking Ridge, N.J. and Munich – (February 3, 2021) -- Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the first patient has been dosed in HERTHENA-Lung01, a ph

Vaxart Announces Positive Preliminary Data from Phase 1 Clinical Trial Evaluating Its Oral COVID-19 Tablet Vaccine Candidate

SOUTH SAN FRANCISCO, Calif., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc., (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral vaccines administered by tablet, today announced pre

Novavax and Government of Switzerland Announce Agreement in Principle to Supply COVID-19 Vaccine

GAITHERSBURG, Md., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that the

GSK and CureVac Develop Next-Generation mRNA Vaccine Against COVID-19

London, UK / Tuebingen, Germany / Boston, USA - February 3, 2021 -- GlaxoSmithKline plc (LSE / NYSE: GSK) and CureVac NV (Nasdaq: CVAC) today announce a new € 150 million collaboration that builds on

Singapore Health Sciences Authority (HSA) Approves Interim Authorization of COVID-19 Vaccine Moderna For Use

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 3, 2021 -- Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the Singapore H

Bristol Myers Squibb and The Rockefeller University Announce License Agreement for SARS-CoV-2 Neutralizing Monoclonal Antibody Combination for the Treatment of COVID-19

NEW YORK--(BUSINESS WIRE) February 3, 2021 -- Bristol Myers Squibb (NYSE: BMY) and The Rockefeller University today announced that they have entered into a definitive agreement under which Bristol Mye

COVID-19 Vaccine AstraZeneca Confirms 100% Protection Against Severe Disease, Hospitalisation and Death in the Primary Analysis of Phase III Trials

3 February 2021 -- The primary analysis of the Phase III clinical trials from the UK, Brazil and South Africa, published as a preprint in The Lancet confirmed COVID-19 Vaccine AstraZeneca is safe and

FDA Approves Ponvory (ponesimod) for the Treatment of Adults with Relapsing Multiple Sclerosis

TITUSVILLE, N.J. – (March 19, 2021) -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) approved Ponvory™ (ponesimod), a o

Sputnik V’s Efficacy in Fighting COVID-19 is Validated by Internationally Peer Reviewed Data Published in The Lancet

Moscow, February 2, 2021 -- The Gamaleya National Research Center of Epidemiology and Microbiology of the Ministry of Health of the Russian Federation and the Russian Direct Investment Fund (RDIF, Rus

Data Presented at WORLDSymposium Reinforces Robust Rare Disease Pipeline and Highlights Additional Clinical Data for Investigational Avalglucosidase Alfa in Pompe Disease

February 2, 2021 -- Data with investigational enzyme replacement therapy avalglucosidase alfa in late-onset Pompe disease (LOPD) and infantile-onset Pompe disease (IOPD) will be featured as platform a

Bristol Myers Squibb Announces Positive Topline Results from Second Pivotal Phase 3 Psoriasis Study Showing Superiority of Deucravacitinib Compared to Placebo and Otezla (apremilast)

PRINCETON, N.J.--(BUSINESS WIRE) February 2, 2021 -- Bristol Myers Squibb (NYSE:BMY) today announced positive results from POETYK PSO-2, the second pivotal Phase 3 trial evaluating deucravacitinib, a